Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (previously presented): A method of removing amyloid deposits from a subject comprising administering to the subject amyloid fibrils in an effective amount to generate an immune response, wherein the immune response promotes the removal of amyloid deposits from the subject.

Claim 2 (previously presented): A method of claim 1, wherein the amyloid fibrils comprise an immunoglobulin light chain polypeptide or a whole immunoglobulin light chain polypeptide.

Claim 3 (currently amended): A vaccine ~~or pharmaceutical~~ composition comprising amyloid fibrils.

Claims 4-31 (canceled)

Claim 32 (previously presented): A method of claim 1 or 2, wherein the amyloid fibrils are synthetic amyloid fibrils.

Claim 33 (previously presented): A method of claim 1 or 2, wherein the amyloid fibrils are recombinant amyloid fibrils.

Claim 34 (previously presented): A method of claim 1 or 2, wherein the amyloid fibrils are naturally occurring amyloid fibrils.

Claim 35 (previously presented): A method of claim 1 or 2, wherein the amyloid fibrils

are homologous amyloid fibrils.

Claim 36 (previously presented): A method of claim 1 or 2, wherein the amyloid fibrils are heterologous amyloid fibrils.

Claim 37 (previously presented): A method of claim 1 or 2, wherein the amyloid fibrils comprise one or more proteins selected from the group consisting of immunoglobulin light chain, serum amyloid A protein, β2-microglobulin, transthyretin, cystatin C variant, gelsolin, procalcitonin, PrP protein, amyloid β-protein, ApoA 1, and lysozyme.

Claim 38 (previously presented): A method of 37, wherein the one or more proteins is a variant or allelic variant thereof.

Claim 39 (previously presented): A method of claim 1 or 2, wherein the subject is a mammal.

Claim 40 (previously presented): A method of claim 39, wherein the mammal is a human.

Claim 41 (currently amended): A method of claim 1, wherein about 10% or more of the amyloid deposits ~~fibrils~~ are removed as compared to the subject without treatment of amyloid fibrils.

Claim 42 (currently amended): A method of claim 41, wherein about 20% or more of the amyloid deposits ~~fibrils~~ are removed as compared to the subject without treatment of amyloid fibrils.

Claim 43 (currently amended): A method of claim 42, wherein about 30% or more of the amyloid deposits ~~fibrils~~ are removed as compared to the subject without treatment of amyloid

fibrils.

Claim 44 (currently amended): A method of claim 43, wherein about 40% or more of the amyloid deposits ~~fibrils~~ are removed as compared to the subject without treatment of amyloid fibrils.

Claim 45 (currently amended): A method of claim 44, wherein about 50% or more of the amyloid deposits ~~fibrils~~ are removed as compared to the subject without treatment of amyloid fibrils.

Claim 46 (currently amended): A vaccine ~~or pharmaceutical~~ composition of claim 3, wherein the vaccine ~~or pharmaceutical~~ composition further comprises a carrier.

Claim 47 (currently amended): A vaccine ~~or pharmaceutical~~ composition of claim 3 or 46, wherein the vaccine ~~or pharmaceutical~~ composition further comprises an adjuvant.

Claim 48 (currently amended): A vaccine ~~or pharmaceutical~~ composition of claim 47, wherein the adjuvant is selected from the group consisting of Freund's, BCG (bacilli Calmette-Guerin), Corynebacterium parvum, aluminum hydroxide (ALUM), lysolecithin, pluronic polyols, polyanions, and dinitrophenol.

Claim 49 (currently amended): A vaccine ~~or pharmaceutical~~ composition of claim 48, wherein the adjuvant is selected from the group consisting of BCG, Corynebacterium parvum, and ALUM.

Claim 50 (currently amended): A method of removing amyloid deposits from a subject comprising administering to the subject amyloid fibrils comprising an immunoglobulin light chain polypeptide ~~and or a whole immunoglobulin light chain polypeptide~~ in an effective amount to generate an immune response, wherein the immune response promotes the removal of amyloid

deposits from the subject.

Claim 51 (previously presented): A method of claim 50, wherein the subject is a mammal.

Claim 52 (previously presented): A method of claim 51, wherein the mammal is a human.

Claim 53 (currently amended): A vaccine ~~or pharmaceutical~~ composition of claim 3 comprising an immunoglobulin light chain polypeptide ~~or a whole immunoglobulin light chain polypeptide~~.

Claim 54 (currently amended): A vaccine ~~or pharmaceutical~~ composition of claim 53, wherein the vaccine ~~or pharmaceutical~~ composition further comprises a carrier.

Claim 55 (currently amended): A vaccine ~~or pharmaceutical~~ composition of claim 54, wherein the vaccine ~~or pharmaceutical~~ composition further comprises an adjuvant.

Claim 56 (previously presented): The method of claim 1 or 2, wherein the amyloid fibrils comprise proteins different from those deposited in the subject.

Claim 57 (currently amended): The method of claim ~~33~~ 32, wherein the ~~recombinant~~ synthetic amyloid fibrils comprise recombinant protein or polypeptide.

Claim 58 (new): A method of removing amyloid deposits from a subject comprising administering to the subject amyloid fibrils comprising a whole immunoglobulin light chain polypeptide in an effective amount to generate an immune response, wherein the immune response promotes the removal of amyloid deposits from the subject and or a whole immunoglobulin light chain polypeptide.

Claim 59 (new): A pharmaceutical composition comprising amyloid fibrils.

Claim 60 (new): A pharmaceutical composition of claim 59 comprising an immunoglobulin light chain polypeptide.

Claim 61 (new) A pharmaceutical composition of claim 59 comprising a whole immunoglobulin light chain polypeptide.

Claim 62 (new): A vaccine composition comprising a whole immunoglobulin light chain polypeptide.

Claim 63 (new) The method of claim 32, wherein the synthetic amyloid fibrils comprise purified native protein or polypeptide.